

Technology Appraisal Committee Meeting (Committee D)

Minutes: Confirmed

Date and Time: Wednesday 28 September 2016: 10.00 – 13.00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:	1. Prof. Gary McVeigh, Chair 2. Dr Lindsay Smith, Vice Chair 3. Dr Andrew Black 4. Dr Matthew Bradley 5. Dr Ian Davidson 6. Prof Simon Dixon 7. Mrs Gillian Ells 8. Prof. Paula Ghaneh 9. Dr Susan Griffin 10. Prof. John Henderson 11. Sumithra Maheswaran 12. Dr David Meads 13. Prof. Oluwafemi Oyebode 14. Dr Mohit Sharma	Present for all notes Present for all notes
-----------------	---	---

In attendance:

Mousumi Biswas	ERG Representative, CRD & CHE – York	Present for all notes
Laura Bojke	ERG Representative, CRD & CHE – York	Present for all notes
Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
David Chandler	Patient expert, CEO, Psoriasis and Psoriatic Arthritis Alliance (PAPAA), nominated by PAPAA	Present for notes 5 to 13
Fadi Chehadah	ERG Representative, CRD & CHE – York	Present for all notes
Mark Corbett	ERG Representative, CRD & CHE – York	Present for all notes
Dr Philip Helliwell	Clinical Expert, Senior Lecturer in Rheumatology, nominated by the British Society for Rheumatology	Present for notes 5 to 13

Dr Ellie Korendowych	Clinical Expert, Consultant Rheumatologist, nominated by the British Society for Rheumatology	Present for notes 5 to 13
Helen Knight	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Kate Moore	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Carla Renton	Patient expert, Information and Communications Manager, Psoriasis Association, nominated by Psoriasis Association	Present for notes 5 to 13
Alex Sexton	Administrator, National Institute for Health and Care Excellence	Present for all notes
Aminata Thiam	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes
Nwamaka Umeweni	Technical Adviser, National Institute for Health and Clinical Excellence	Present for all notes

Notes

Welcome

1. The Vice Chair welcomed all members of the Committee and other attendees present to the meeting. The Vice Chair reviewed the agenda and timescales for the meeting, which included the appraisals of certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs.
2. The Vice Chair welcomed Sumithra Maheswaran to her first meeting as a voting member of the Appraisal Committee
3. Apologies were received from Dr Aomesh Bhatt, Professor David Bowen, Dr Ian Campbell, Ms Tracey Cole, Mrs Susan Dutton, Mr Malcolm Oswald and Dr Paula Parvulescu.

Any other Business

4. None.

Appraisal of certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs

Part 1 – Open session

5. The Vice Chair welcomed the invited experts: Mousumi Biswas, Laura Bojke, David Chandler, Fadi Chehadah, Mark Corbett, Dr Philip Helliwell, Dr Ellie Korendowych and Carla Renton to the meeting and they introduced themselves to the Committee.

6. The Vice Chair welcomed company representatives from Novartis and UCB Pharma to the meeting.
7. The Vice Chair asked all Committee members to declare any relevant interests
 - 7.1. Dr Andrew Black, Dr Matthew Bradley, Dr Ian Davidson, Mrs Gillian Ells, Professor Paula Ghaneh, Ms Sumithra Maheswaran, Professor Gary McVeigh, Dr David Meads, Professor Oluwafemi Oyebode, Dr Mohit Sharma and Dr Lindsay Smith all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs.
 - 7.2. Professor Simon Dixon declared a non-personal non-specific financial interest as he is Director of a Health Economics Unit that has undertaken work for Novartis on unrelated topics and the University of Sheffield has received payment for this work. He had not been directly involved in the work.
 - 7.2.1 It was agreed that this declaration would not prevent Professor Simon Dixon from participating in this section of the meeting.
 - 7.3. Dr Susan Griffin declared a personal non-specific financial interest as she had taken part in an Advisory Board and was personally reimbursed by Novartis in November 2015. The topic of the Advisory Board related to non small cell lung cancer.
 - 7.3.1 It was agreed that this declaration would not prevent Dr Susan Griffin from participating in this section of the meeting.
 - 7.4. Professor John Henderson declared a personal non-specific financial interest as he had received an honorarium from Novartis in relation to a speaking engagement.
 - 7.4.1 It was agreed that this declaration would not prevent Professor John Henderson from participating in this section of the meeting.
8. The Vice Chair asked all NICE Staff to declare any relevant interests.
 - 8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs.
9. The Vice Chair asked all other invited guests to declare their relevant interests.
 - 9.1. Mousumi Biswas, Laura Bojke, David Chandler, Fadi Chehadah, Mark Corbett, and Carla Renton declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family

interest for any of the technologies to be considered as part of the appraisal of certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs.

9.2. Dr Ellie Korendowych declared a personal non-specific financial interest as she had done non-promotional education meetings for UCB and Novartis.

9.2.1. It was agreed that this declaration would not prevent Dr Ellie Korendowych from participating in this section of the meeting.

9.3. Dr Philip Helliwell declared a personal non-specific financial interest as he had done non-promotional work supported by UCB.

9.3.1. It was agreed that this declaration would not prevent Dr Philip Helliwell from participating in this section of the meeting

10. The Vice Chair introduced Dr Andrew Black, who gave a presentation on the clinical effectiveness of certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs; he himself gave a presentation on the cost effectiveness.

11. The Vice Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Vice Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

13. The Vice Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease modifying anti-rheumatic drugs.

16. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

17. Wednesday 26 October, 10.00 – 17.00, at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.